Erythritol had a bad news cycle. Here is what the study actually measured.

If you searched erythritol any time after early 2023, you met a wall of headlines connecting it to heart attacks and strokes. The underlying research is real and worth taking seriously. It also does not say what most of the coverage said it said.

What the paper did

The work combined two very different things.

The first was observational: measuring blood erythritol in patients already undergoing cardiac risk assessment, then following who had events. Higher circulating erythritol tracked with higher event rates.

The second was mechanistic: laboratory and short-term human work suggesting erythritol can promote platelet aggregation — the clumping step in clot formation.

Why the observational half is hard to read

Humans make erythritol endogenously. Your body produces it from glucose through the pentose phosphate pathway, and production rises under metabolic stress — exactly the conditions that also predict cardiovascular events.

So a high blood level can mean "this person consumes erythritol" or "this person's metabolism is producing more of it." The study population was people already referred for cardiac evaluation, which is a group enriched for the second explanation. Association in that setting cannot separate the two, and the authors were clearer about this than the headlines were.

Why the mechanistic half still matters

The platelet work is the part that should not be waved away. It proposes a plausible mechanism rather than a correlation, and the doses used were within reach of what a heavy consumer of sugar-free products might encounter.

What it does not establish is that ordinary intake produces clinically meaningful risk in ordinary people over ordinary timeframes. That requires different studies, and they have not been done yet.

Where that leaves it

Erythritol remains approved in both the US and EU, and the regulatory reviews predate this paper. It also remains the best-tolerated sugar alcohol by a wide margin, which is a real benefit against a real and common downside in the alternatives.

The honest position is that this is unsettled, that the finding deserves follow-up, and that neither "erythritol causes heart attacks" nor "the study was debunked" is supportable. If you want to be conservative while it is unresolved, the lever is dose, not avoidance.

Our erythritol report lists the regulatory status, the intake levels assessed, and the findings alongside their limitations. It will change when the evidence does.